BKM120 (NVP-BKM120, Buparlisib) 化学構造
分子量: 410.39

高品質保証

文献中の引用(34)

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • BKM120 (NVP-BKM120, Buparlisib)のメカニズム

製品の説明

生物活性

製品説明 BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。
ターゲット p110α p110β p110δ p110γ
IC50 52-99 nM 166 nM 116 nM 262 nM [1]
In vitro試験 BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF7 M1PzN2N6fG:2b4jpZ{BCe3OjeR?= MkK2O|IhcA>? Mmf2SG1UVw>? M2fGdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFiRUW0OWshdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFE2QCEQvF2= MU[yOFkxODJ4Nh?=
DU145 NVvBTWx{S3m2b4TvfIlkKEG|c3H5 NH3QVYY4OiCq NUjiZ3NqTE2VTx?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? M2rYSVI1QTByMk[2
A2780 NX\xUlFtS3m2b4TvfIlkKEG|c3H5 NVziWnh5PzJiaB?= M3zCSWROW09? MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP MoDYNlQ6ODB{Nk[=
U87MG M1\ZbGN6fG:2b4jpZ{BCe3OjeR?= NGXhXYo4OiCq Ml7kSG1UVw>? M2D6XmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= MVKyOFkxODJ4Nh?=
A2780 Ml;HSpVv[3Srb36gRZN{[Xl? NVj5UHpKOSCq M3LY[mROW09? NVz0PHdSUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= NYK5PWhrOjR7MECyOlY>
DU145 NYLnXGU3TnWwY4Tpc44hSXO|YYm= MkTPNUBp M{T2dmROW09? M2jGV2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBFXTF2NTDj[YxteyCqYYLic5JqdmdiTFvCNUBufXSjdHnvckB4cXSqIFXDOVAhd2ZiMD6wO|Mh|ryP NYW5TnZnOjR7MECyOlY>
A2780 NHPMc4tHfW6ldHnvckBCe3OjeR?= NVPxfXBEOSCq NFTDVIhFVVOR NEe5PWZKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDFR|UxKG:oIECuNFc1KM7:TR?= Mk\CNlQ6ODB{Nk[=
MCF7 M1PVUWZ2dmO2aX;uJGF{e2G7 NYXjbFlWOSCq NHXBOZVFVVOR NUnrenREUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgSVU1PUtibYX0ZY51NW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlEh|ryP M3jPS|I1QTByMk[2
U87MG MYfGeY5kfGmxbjDBd5NigQ>? NUnhOFJkOSCq MV7EUXNQ NVjMSXJEUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= MkjjNlQ6ODB{Nk[=
A2780 NYTkZmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi3NkBp NGPrVJFFVVOR MWDFR|UxRTBwNUKg{txO MWiyOFkxODJ4Nh?=
SKMES-1 NIO0fHZEgXSxdH;4bYMhSXO|YYm= MXqxJO69VQ>? MWm3NkBp MVLJcoR2[2W|IHPlcIwh\GWjdHi= MVmyOlAyOzNzOB?=
H596 M1LVbGZ2dmO2aX;uJGF{e2G7 MnXwNUDPxE1? NUTkWmJtUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= NEHyS2QzPjBzM{OxPC=>
HCC2450 M2\oeWZ2dmO2aX;uJGF{e2G7 MmTYNUDPxE1? M3fkdWlueGGrcoOgZ4VtdCCrbo\hd4lwdg>? M2nQNlI3ODF|M{G4
A549 M3\NS2Z2dmO2aX;uJGF{e2G7 MU[1NFAhdk1? Mk\yOFghcA>? MYXEUXNQ M1nF[GlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w NHPHO3ozPTl|N{K5PS=>
A549 M1PJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPHNoY1OSEQvF2= NWW1ZnFPPzJiaB?= M{DkPGROW09? NGPrcmxKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M1;JOFI2QTN5Mkm5
H522 NIe1c4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxJO69VQ>? MofqO|IhcA>? MkjmSG1UVw>? NXXxV29KUW6qaXLpeJMh[2WubDDndo94fGh? MVyyOVk{PzJ7OR?=
LNCaP M3f1eWZ2dmO2aX;uJGF{e2G7 M3HId|Eh|ryP NXTWXWk4W3WycILld5NmeyCyLVHLWEBt\X[nbIO= NXLzbIhjOjV|NkC3PVk>
LNCaP95 MnzsSpVv[3Srb36gRZN{[Xl? NYP5Z2h3OSEQvF2= MV7TeZBxemW|c3XzJJAuSUuWIHzleoVtew>? NFLzOoszPTN4MEe5PS=>
HCT-15 MWjBdI91d3OrczDBd5NigQ>? MXixNEDPxE1? M2PjNVQ5KGh? NFvUSo9FVVOR M1fsO2lv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xOUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NUXz[XlXOjVzNUKyOFU>
HCT-116 NYrxdW9LSXCxdH;zbZMhSXO|YYm= NFPrRpIyOCEQvF2= M4rzRlQ5KGh? MnroSG1UVw>? MVrJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? M2jV[FI2OTV{MkS1
NCI-H460 NGDUTJNCeG:2b4Ppd{BCe3OjeR?= Mk\wNVAh|ryP MoXYOFghcA>? MoHwSG1UVw>? MXHJcoR2[2W|IHHwc5B1d3OrczDpckBPS0lvSES2NEBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MYCyOVE2OjJ2NR?=
SKOV-3 MorqRZBwfG:|aYOgRZN{[Xl? NIjET4YyOCEQvF2= Mor0OFghcA>? NFXTe2hFVVOR NVO0WYFVUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= NFrNN4EzPTF3MkK0OS=>
BSY-1 Mk\1RZBwfG:|aYOgRZN{[Xl? NYKzWGJCOTBizszN MWC0PEBp NIPpW3ZFVVOR MXfJcoR2[2W|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v MVWyOVE2OjJ2NR?=
MKN-1 MYHBdI91d3OrczDBd5NigQ>? M4nrNVExKM7:TR?= NXXOVZV3PDhiaB?= NIfiVI9FVVOR MY\JcoR2[2W|IHHwc5B1d3OrczDpckBOU05vMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v Mmm4NlUyPTJ{NEW=
NCI-H522 NFTLS2RCeG:2b4Ppd{BCe3OjeR?= M2P0W|ExKM7:TR?= NV\2d5NxPDhiaB?= M1TYWmROW09? MorZTY5lfWOnczDhdI9xfG:|aYO= Mlq3NlUyPTJ{NEW=
OVCAR-3 MYTBdI91d3OrczDBd5NigQ>? MX2xNEDPxE1? NV3ZclFyPDhiaB?= MoPNSG1UVw>? MXLJcoR2[2W|IHHwc5B1d3Orcx?= M{XvXVI2OTV{MkS1
HBC-5 MVvBdI91d3OrczDBd5NigQ>? M1;KfFExKM7:TR?= MVq0PEBp NWTVdFVpTE2VTx?= NV;qclNHUW6mdXPld{BieG:ydH;zbZM> NFX0ZZAzPTF3MkK0OS=>
RXF-631L NWHsVVZRSXCxdH;zbZMhSXO|YYm= NGfzZYEyOCEQvF2= M1zpS|Q5KGh? NWX3NW1lTE2VTx?= MkiwTY5lfWOnczDhdI9xfG:|aYO= M1fVUVI2OTV{MkS1
MKN-45 NWrUTVRPSXCxdH;zbZMhSXO|YYm= NE[zO3kyOCEQvF2= M2XCclQ5KGh? NFrmWnNFVVOR MnzWTY5lfWOnczDhdI9xfG:|aYO= M2DjcVI2OTV{MkS1
BON-1 NXezdVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonkOVAxKG6P M2CzVlExKGR? NIridJpFVVOR M{TEcmlvcGmkaYTzJINmdGxiZ4Lve5Rp NGjSbnQzPTB{NkK5Ni=>
BON-1 MUnGeY5kfGmxbjDBd5NigQ>? Mn3MOVAxKG6P M2DTOlQhcA>? M1;mdWROW09? M4G4VWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= M3v3bVI2ODJ4Mkmy
QGP-1 NGX2S3JHfW6ldHnvckBCe3OjeR?= NYWxWGNRPTByIH7N MkjJOEBp NHP3XmpFVVOR Moi4TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= NU\1WYZjOjVyMk[yPVI>
Huh7 MkTqSpVv[3Srb36gRZN{[Xl? NHPiN5IyKM7:TR?= M3HiOFEhcA>? Mn7pSG1UVw>? M{jGXmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgV4VzPDd2 M2jQ[VI2ODB2NECz
BNL NYDXXI1lTnWwY4Tpc44hSXO|YYm= NIDWZ3MyKM7:TR?= M2TBblEhcA>? NUTNc25jTE2VTx?= NVTkN44yUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4 Mn7SNlUxODR2MEO=
MDA-MB-175 NH7ocFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr0V3pxOSEQvF2= NGq0fnY2KGR? NHjBZYZFVVOR NWjxW4NTUUN3MEyxJO69VQ>? M1[2d|I1QDd7N{m2
MDA-MB-134 M3;Udmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj0NUDPxE1? MkO5OUBl NVOwT4E2TE2VTx?= MVrJR|UxRDFizszN MVWyOFg4QTd7Nh?=
HCC1500 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvtR2w1OSEQvF2= NX3HVWJkPSCm MUTEUXNQ MXvJR|UxRDFizszN MV[yOFg4QTd7Nh?=
EFM-19 NGfsS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X2b|Eh|ryP MlPJOUBl MUDEUXNQ MoHtTWM2ODxzIN88US=> MmXRNlQ5Pzl5OU[=
ZR-75-30 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexJO69VQ>? MXG1JIQ> MXLEUXNQ NV3NRYdGUUN3MEyxJO69VQ>? NU\yWWV6OjR6N{m3PVY>
MDA-MB-361 NFi2S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxJO69VQ>? NUe1b4E5PSCm Ml\0SG1UVw>? NGLoV2RKSzVyPEGg{txO MnfHNlQ5Pzl5OU[=
T-47D MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nyN|Eh|ryP NUfB[JJRPSCm MV3EUXNQ M3PMdmlEPTB:MTFOwG0> MV[yOFg4QTd7Nh?=
SK-BR-3 M1XSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D5VlEh|ryP MWW1JIQ> NEDZSGdFVVOR NVfoN41LUUN3MEyxJO69VQ>? M4TvdVI1QDd7N{m2
UACC-732 NX;4NFhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDHOYlmOSEQvF2= NYPI[YRIPSCm MWrEUXNQ Mn7BTWM2ODxzIN88US=> MWSyOFg4QTd7Nh?=
BT-474 M4PvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe2RogyKM7:TR?= MXu1JIQ> NXz1Uoh{TE2VTx?= MYLJR|UxRDFizszN M33MflI1QDd7N{m2
HCC202 NYfBfZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TTeFEh|ryP MmnGOUBl NWrwV4tzTE2VTx?= MlvmTWM2ODxzIN88US=> NFnZVlczPDh5OUe5Oi=>
MCF7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXjNUDPxE1? M2DYTlUh\A>? M3LYTmROW09? MkHBTWM2ODxzIN88US=> MkW4NlQ5Pzl5OU[=
MDA-MB-415 M1j2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;XWlEh|ryP MWO1JIQ> NIq2TGRFVVOR MVXJR|UxRDFizszN NH3WZ5QzPDh5OUe5Oi=>
MDA-MB-453 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xJO69VQ>? M3rSdFUh\A>? MV;EUXNQ M2nO[GlEPTB:MTFOwG0> NEHoRYgzPDh5OUe5Oi=>
ZR-75-1 MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Tre|Eh|ryP MW[1JIQ> M{HrdmROW09? Mk\yTWM2ODxzIN88US=> MWCyOFg4QTd7Nh?=
HCC38 M2PHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixJO69VQ>? Ml;pOUBl NYPkXVVVTE2VTx?= NHzNenpKSzVyPEGg{txO MUKyOFg4QTd7Nh?=
HCC1419 NVvDXpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKwSWQyKM7:TR?= NIPCc5o2KGR? NHG0R|NFVVOR M1jLV2lEPTB:MTFOwG0> NF\EW3YzPDh5OUe5Oi=>
UACC-812 M4DyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjsWHEyKM7:TR?= NGP2WWI2KGR? NWrnWGRITE2VTx?= MWjJR|UxRDFizszN MV:yOFg4QTd7Nh?=
HCC1187 M1TtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILw[ngyKM7:TR?= Ml\FOUBl NGraZ2xFVVOR NILqdmVKSzVyPEGg{txO NXvITWhnOjR6N{m3PVY>
KPL-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LZd|Eh|ryP NH\qZ|k2KGR? NH;xSGNFVVOR MnK1TWM2ODxzIN88US=> MoD5NlQ5Pzl5OU[=
SUM-225 NIP5RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvJNUDPxE1? MkfLOUBl NFLUbmlFVVOR NXjXPFd1UUN3MEyxJO69VQ>? MXeyOFg4QTd7Nh?=
EFM-192A NGfmdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHvUIIyKM7:TR?= MmTaOUBl Ml;lSG1UVw>? M3;xUmlEPTB:MTFOwG0> NG\Nc24zPDh5OUe5Oi=>
JIMT-1 NXzOSHByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ONUDPxE1? MX:1JIQ> NIrieWtFVVOR MYPJR|UxRDFizszN M3TQUVI1QDd7N{m2
HCC1143 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELUXosyKM7:TR?= MYC1JIQ> NFHrXnhFVVOR MonxTWM2ODxzIN88US=> NGDGNFkzPDh5OUe5Oi=>
HCC2218 NIHhRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\vNUDPxE1? MkOxOUBl MmDFSG1UVw>? NFe3UnBKSzVyPEGg{txO M3XOTlI1QDd7N{m2
MDA-MB-468 M3jpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xJO69VQ>? NWTzdlF2PSCm M{fMc2ROW09? MVTJR|UxRDFizszN NX;Se45vOjR6N{m3PVY>
BT-20 NXLoTohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXexJO69VQ>? NIHoRpE2KGR? NH3wWVJFVVOR NFXscXZKSzVyPEGg{txO MVWyOFg4QTd7Nh?=
MDA-MB-435 NGLoOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnQNJAyKM7:TR?= NUHIS3hjPSCm MXHEUXNQ Mn3vTWM2ODxzIN88US=> MmLpNlQ5Pzl5OU[=
BT-549 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zieFEh|ryP MX[1JIQ> NHLqTlNFVVOR MlzXTWM2ODxzIN88US=> NVK2eFNyOjR6N{m3PVY>
HCC1806 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTrR2pnOSEQvF2= MnnYOUBl NIfEe3RFVVOR M1j2c2lEPTB:MTFOwG0> Ml65NlQ5Pzl5OU[=
HCC1937 NHvlSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDLW5gyKM7:TR?= MoryOUBl NX7O[lUzTE2VTx?= NHPZUYxKSzVyPEGg{txO NEGzcJAzPDh5OUe5Oi=>
Hs578T M1u2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexJO69VQ>? MljQOUBl NGK1VHZFVVOR M2i0NWlEPTB:MTFOwG0> M2TNXlI1QDd7N{m2
LN18 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LBclIxKM7:TR?= M3L3bFczKGh? M3XuXmROW09? MoL2TWM2ODx3IN88US=> NIDMUGszPDd2MUC3OC=>
LN229 M4rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rabFIxKM7:TR?= MVK3NkBp MXjEUXNQ NXPhZ3RFUUN3MEy1JO69VQ>? NV7HZ3NCOjR5NEGwO|Q>
LNZ308 NIfTdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\xd4szOCEQvF2= MVy3NkBp MYTEUXNQ MmrLTWM2ODx3IN88US=> MV:yOFc1OTB5NB?=
T98G M3zodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHpNlAh|ryP Mn;DO|IhcA>? MVrEUXNQ MYjJR|UxRDVizszN M1;STlI1PzRzMEe0
U87 M2\5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\aPFIxKM7:TR?= NUfzd4lGPzJiaB?= NIG0cm1FVVOR NWTYcIN2UUN3MEy1JO69VQ>? NIDXTZUzPDd2MUC3OC=>
LN18 MWTGeY5kfGmxbjDBd5NigQ>? NFrn[Wc2KM7:TR?= NYPBWng3OjRiaB?= Mli5SG1UVw>? MoG5TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NXPMXGxWOjR5NEGwO|Q>
LNZ308 Mlu1SpVv[3Srb36gRZN{[Xl? NEWyPJc2KM7:TR?= MVOyOEBp NXv4NG5XTE2VTx?= NEXXOHlKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW Ml;HNlQ4PDFyN{S=
Saos-2 Mo\xSpVv[3Srb36gRZN{[Xl? MoS0OVAh|ryP NELyXFg1QCCq Mkf4TY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NFrr[nIzPDd{N{[2NC=>
MG-63 M1f1cGZ2dmO2aX;uJGF{e2G7 M1f3T|UxKM7:TR?= MlzIOFghcA>? M4riTWlvcGmkaYTzJINmdGxiaX72ZZNqd25? MYWyOFczPzZ4MB?=
SJSA-1 MYnGeY5kfGmxbjDBd5NigQ>? MY[1NEDPxE1? M1PLNFQ5KGh? MoTQTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? Mmj6NlQ4Ojd4NkC=
Saos-2 MnXlSpVv[3Srb36gRZN{[Xl? MmHBOVAh|ryP NVnXVWRQPDhiaB?= MmfLTY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> M{H1T|I1PzJ5Nk[w
MG-63 NWnCRXdZTnWwY4Tpc44hSXO|YYm= NHfOb4I2OCEQvF2= Ml;KOFghcA>? NInmbpJKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MWmyOFczPzZ4MB?=
SJSA-1 MnfjSpVv[3Srb36gRZN{[Xl? NWj0e5g5PTBizszN NGXkTWE1QCCq NGLhdZRKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NV\adlM6OjR5Mke2OlA>
Saos-2 NYPHTZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPsb4FZPTBizszN M1;nW|Q5KGh? M3\lfGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NVTrWWxDOjR5Mke2OlA>
MG-63 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP0U5ZOPTBizszN NEGxemY1QCCq MnXETY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M1fSTVI1PzJ5Nk[w
SJSA-1 NF7PSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHMZ21vPTBizszN NX\kR3JsPDhiaB?= M2nT[mlvcGmkaYTzJINmdGxidnnhZoltcXS7 MmL5NlQ4Ojd4NkC=
FaDu MmOwSpVv[3Srb36gRZN{[Xl? M1\ReFUh|ryP NHvZXGwzPCCq MoG4SG1UVw>? M3nxTXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u MXiyOFY{OTF2Nx?=
EMT6 M4\KcGZ2dmO2aX;uJGF{e2G7 MXq1JO69VQ>? NWLRdZJvOjRiaB?= M2PxdGROW09? NUfjOGxXWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> M3Ha[FI1PjNzMUS3
HCT116 NHnsbHVHfW6ldHnvckBCe3OjeR?= MXi1JO69VQ>? MVGyOEBp NHn0[YlFVVOR MoHxVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NVrpTJJuOjR4M{GxOFc>
U87 NWHIN5lMTnWwY4Tpc44hSXO|YYm= NXzmb3ZSPSEQvF2= MWSyOEBp MXXEUXNQ MYTS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= M{XkeVI1PjNzMUS3
GBM MlXzRZBweHSxc3nzJGF{e2G7 M13TcVLPxE1? NXWzeG9qPDiq Ml7kSG1UVw>? MljCbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> NGDJ[IYzPDVyMES5Ni=>
BON M2TpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHVNU02|ryP MUC3Nog> M4[2cIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> NYPjPVZsOjR2NEO1NlM>
BON MWrBdI9xfG:|aYOgRZN{[Xl? MXmxMVXPxE1? NXn2U5NQOjSq NVTsO2lKcW6lcnXhd4V{KGGyb4D0c5Nqew>? NVzPdJRpOjR2NEO1NlM>
H1975 M4PIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6V2oxNjNvOT62{txO MYG3Nog> MofwSG1UVw>? MnLYTWM2OD1zLkO4Oe69VQ>? M4TURlI1OzN5OES2
H1975 M2C5cWFxd3C2b4Ppd{BCe3OjeR?= NV65XlZIOs7:TR?= M{X1O|I1cA>? MmnpSG1UVw>? NXPkPJRtcW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? NH;OfWgzPDN|N{i0Oi=>
T-ALL NFfyVY9CeG:ydH;zbZMhSXO|YYm= M{LuUoJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= NUHybIlJOjRib4KgOFhp MX;EUXNQ MXHh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= Mk\qNlQ{OTB5M{[=
BCR-ABL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3pNE4zPS1zMN88US=> MoPTOIQ> NIrY[IV{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w MojzNlQzPDR4MUK=
LC-1/SQSF MkfXSpVv[3Srb36gRZN{[Xl? NXLSWXBKO87:TR?= MnTzNlRp MnvpSG1UVw>? MnLM[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs MnfuNlM6QDByOUO=
Primary CLL cells NHPIdZhCeG:ydH;zbZMhSXO|YYm= NUPPOJNrOS1zMN88US=> NFLCeW81QGh? MonhbY5lfWOnczDhdI9xfG:|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=> MYCyN|g2ODhyNx?=
Primary CLL cells M{\Tc2tqdmG|ZTDBd5NigQ>? M1rOclLPxE1? M4i0W|MxdWmw MVzk[YNz\WG|ZXSgVGk{UyCjY4Tpeol1gQ>? M2LvWVI{QDVyOEC3
Primary CLL cells MlXaR5l1d3SxeHnjJGF{e2G7 NVfpT4luOs7:TR?= NFTIXJczPGh? MorzbY5lfWOnczDj[YxtKGO7dH;0c5hq[2m2eR?= NGnUToczOzh3MEiwOy=>
human NSCLC cell lines M1zq[2Fxd3C2b4Ppd{BCe3OjeR?= NVP2c3hZOC5zMkWtOO69VQ>? NGT4[nYzPGh? MnfFSG1UVw>? NV\5NnZSUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> MWmyN|U3OjR5Mh?=
human HCC cell lines MVzD[YxtKH[rYXLpcIl1gSCjc4PhfS=> MUWwMlAxPS1zzszN NU\3SHR6PDiq M17ZPWlEPTB;Md88US=> MmfRNlM1QDl7OUm=
Huh7 MnTCT4lv[XOnIFHzd4F6 MnXFNe69VQ>? MlzuOFhp M3PZUJNq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> NEnmV4czOzR6OUm5PS=>
SK-HEP1 NXO0WWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TIT|EuOjEQvF2= NUjwPJhxPzKq M3LIPWROW09? M{TTe2lEPTExvKyx{txO NUCwU4ZqOjN2N{mxN|Y>
786-0 NYGxOmhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHpNYIyNTJyzszN MmHCO|Jp NIS3UItFVVOR NIXqRZVKSzVy78{cNe69VQ>? NIS0c5kzOzR5OUGzOi=>
JVM2 Mnz1R5l1d3SxeHnjbZR6KGG|c3H5 NH;SR|kxNjJvMkFOwG0> NULBNplUPzKq NX\hZppXTE2VTx?= MVvJR|UxRTBwOd88US=> NW\tNFNCOjN{M{i2N|k>
EHEB MorhR5l1d3SxeHnjbZR6KGG|c3H5 NGLEbnUxNjJvMkFOwG0> MYS3Nog> MU\EUXNQ MUTJR|UxRTBwN988US=> M4L1[|I{OjN6NkO5
MEC2 M1;WV2N6fG:2b4jpZ4l1gSCjc4PhfS=> NUSxSlI6OC5{LUKw{txO MVy3Nog> MmTWSG1UVw>? NVPkOGtDUUN3ME2wMlfPxE1? MlXiNlMzOzh4M{m=
primary B-CLL lymphocytes M4njRWFxd3C2b4Ppd{BCe3OjeR?= MmXRTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? MkXWNlRp M4DwXmROW09? NFrHbY1KSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ MUmyN|I{QDZ|OR?=
primary B-CLL lymphocytes Moj2T4lv[XOnIFHzd4F6 NHTpUmdKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n M2rOblI1cA>? MoDDbY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= MoPvNlMzOzh4M{m=
human NSCLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHFVHplOC53LUNOwG0> M4\ZVVczcA>? M2fYVGlEPTB;Md88US=> MnHGNlI4QDF|OUO=
human NSCLC NWHrb2FnU2mwYYPlJGF{e2G7 MlzjNe69VQ>? NYCwN|Z2OjSq NGi2ZppqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 MkWwNlI4QDF|OUO=
Y1 cell line MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGwMlHPxE1xMd88US=> MV2yOIg> NIXVXWNFVVOR M4L1ZolvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy| NYrXVZZmOjJ4OUK5NFQ>
PIK3CA-mutant MCF7 NGLifVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\tN2NTT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= Mm\oO|Jp NGDEe2VIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= NUDXR5JmOjJ4NUO5Olc>
PIK3CA-mutant MCF7 NUDRXXV1U2mwYYPlJGF{e2G7 MWHJR|UxRTFzNNMxN45O M{DRRlczcA>? M4Pwc2lEPTB;MUG0xtE{dk1iaX6gdoVlfWOrbnegRYt1KHCqb4PwbI9zgWyjdHnvckBt\X[nbIO= MWCyNlY2Ozl4Nx?=
MCF7-myr-Akt MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnXZVZIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= NYi0dpNGPzKq NX3UN2dFT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= MXKyNlY2Ozl4Nx?=
colon cancer cell lines NIfmb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX1OFNvOC1zMN88US=> MYG3Nog> NWPYTYxWTE2VTx?= M1n4[mlEPTB;Md88US=> NIOxbmgzOjV2M{i1Oy=>
gastric cancer cell lines NITMcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDrNE0yOM7:TR?= MX63Nog> M{PQemROW09? MoCwTWM2OD1{LUZOwG0> Mn\YNlI2PDN6NUe=
HCT-116/HT-29/MKN-45 NVrv[5lXSXCxcITvd4l{KEG|c3H5 M1vVbFLPxE1? MWG0PIg> M1ziOJNpcW[2IHnuJGczKHCqYYPl MUWyNlU1Ozh3Nx?=
HT-29 and HCT-116 NVXsTZFPS2G|cHHz[UBie3OjeR?= NU\IXIo2Pc7:TR?= NFzMXJYzPGh? MV3pcoR2[2W|IHPhd5Bie2ViYXP0bZZqfHl? M{\DXFIzPTR|OEW3
MM cell lines NF[5[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PYc|Ex|ryP M4PJd|I1cA>? MXPEUXNQ MUnJR|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U> MYiyNlIxPzR6NR?=
ARP-1 Ml;JRZBweHSxc3nzJGF{e2G7 MmLRNVDPxE1? MmPjNlRp M1HZbGROW09? NInLUIRqdmS3Y3XzJG1OKGOnbHygZZBweHSxc3nzJJRpem:3Z3igZ4F{eGG|ZTDhZ5RqfmG2aX;u M1n4c|IzOjB5NEi1
SNU-601 NX;IZZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3Nog> NVvZTFI2TE2VTx?= MUnJR|UxRTBwOEG2xtExNjB4M988US=> MUeyNlE2QThzNB?=
SNU-1 NWfUeYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HEc|czcA>? Mn\sSG1UVw>? NX3MemY2UUN3ME2xMlA5OsLzMD6wNljPxE1? MYOyNlE2QThzNB?=
SNU-668 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYO|Jp M{LFTGROW09? NYi1cHBrUUN3ME2xMlU4QcLzMD6wO|TPxE1? MmD2NlIyPTl6MUS=
AGS Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLD[nA4Omh? MoTHSG1UVw>? NITSN5ZKSzVyPUGuO|E1yrFyLkGxO:69VQ>? M3[xdVIzOTV7OEG0
SNU-216 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfwb2ZsPzKq MV3EUXNQ M2T3dWlEPTB;Mj62PVLDuTBwMEiy{txO NFnPWWszOjF3OUixOC=>
SNU-5 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;SO|Jp MWXEUXNQ NES4U|RKSzVyPUGuN|UyyrFyLkC5Ne69VQ>? MWWyNlE2QThzNB?=
SNU-638 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nLcFczcA>? MlvGSG1UVw>? M3XxOWlEPTB;Mj6yPFLDuTBwMEWz{txO NIHXU4gzOjF3OUixOC=>
SNU-16 M3XJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zBNFczcA>? MX;EUXNQ MmHZTWM2OD1zLkW3N:KyOC5yMEJOwG0> NGW2Z|kzOjF3OUixOC=>
SNU-484 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDyOXE4Omh? MUnEUXNQ NVjGNoZJUUN3ME2xMlczQMLzMD6wOFXPxE1? MV[yNlE2QThzNB?=
SNU-620 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1fpk4Omh? MmDXSG1UVw>? MlezTWM2OD1{LkmzPeKyOC5yMEJOwG0> NHPqbnYzOjF3OUixOC=>
SNU-719 M33BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4UFczcA>? M4\VU2ROW09? Mn[yTWM2OD1|LkCzO:KyOC5yM{NOwG0> NX2xZXluOjJzNUm4NVQ>
glioma cell lines MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3Nog> NI\QfYdKSzVyPUGtNu69VQ>? Ml;sNlIxPjVyOEC=
U87 NVTZfphwSXCxcITvd4l{KEG|c3H5 MWGy{txO MXu3Nog> MofvbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO= M4XlWVIzODZ3MEiw

... Click to View More Cell Line Experimental Data

In vivo試験 BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]
臨床試験 Current under Phase II in men with metastatic castration-resistant prostate cancer.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

PI3K biochemical assay (ATP depletion assay) BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
PI3K biochemical assay (filter binding assay) 50 µL/well of a 1:1 mixture of 100 µL/mL L-α-phosphatidylinositol and L-α-phosphatidylserine dissolved in chloroform:ethanol (2.2:7.8) is pipetted into 96-well MaxiSorpTM plates. The solvents are evaporated at room temperature and plates are wa

細胞アッセイ: [1]

細胞株 A2780 cells.
濃度 0-6.6 μM
反応時間 3 days.
実験の流れ A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.

動物実験: [1]

動物モデル U87MG and A2780 xenografts are established in female nu/nu mice.
製剤 In 15% Captisol.
投薬量 ~60 mg/kg.
投与方法 Dosed orally daily (q.d.).

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download BKM120 (NVP-BKM120, Buparlisib) SDF
分子量 410.39
化学式

C18H21F3N6O2

CAS No. 944396-07-0
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 82 mg/mL (199.8 mM)
エタノール 2 mg/mL (4.87 mM)
<1 mg/mL (<1 mM)
In vivo 0.5% CMC Na 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

文献中の引用 (34)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

最近チェックしたアイテム

Tags: BKM120 (NVP-BKM120, Buparlisib)を買う | BKM120 (NVP-BKM120, Buparlisib)供給者 | BKM120 (NVP-BKM120, Buparlisib)を購入する | BKM120 (NVP-BKM120, Buparlisib)費用 | BKM120 (NVP-BKM120, Buparlisib)生産者 | オーダーBKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ